Ascendis Pharma A (ASND) Equity Income (2023 - 2026)

Ascendis Pharma A has reported Equity Income for 8 years, with the latest figure at -$12.0 million in Q1 2026.

• Quarterly Equity Income fell 142.93% year-over-year to -$12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.9 million (down 290.26% YoY) and the FY2025 annual result came in at $19.0 million, up 188.56% from the prior year.
• Equity Income slipped to -$12.0 million in Q1 2026 per ASND's latest filing, from $1.5 million in the prior quarter.
• Over five years, Equity Income peaked at $28.0 million in Q1 2025 and troughed at -$12.0 million in Q1 2026.
• A 5-year average of -$2.7 million and a median of -$4.8 million in 2024 frame the typical range for Equity Income.
• The sharpest annual moves came in 2023 and 2025: Equity Income sank 552.12% in 2023, then surged 544.02% in 2025.
• Over 5 years, Equity Income stood at -$8.1 million in 2022, then soared by 61.27% to -$3.1 million in 2023, then slumped by 55.4% to -$4.9 million in 2024, then jumped by 131.62% to $1.5 million in 2025, then sank by 876.36% to -$12.0 million in 2026.
• According to Business Quant data, Equity Income over the past three periods registered -$12.0 million, $1.5 million, and -$8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.